This is in part explained by the fact that while patients with HER2 + and triple negative disease are over-represented in this sample, most patients with LMD in our series had HR+/HER2− disease and no systemic targeted therapy has demonstrated efficacy in treatment of LMD. This evidence concerns the gene ERBB2 and Langer mesomelic dysplasia.